公开(公告)号：US20190314291A1

公开(公告)日：2019-10-17

申请号：US16262758

申请日：2019-01-30

Applicant: ModernaTX, Inc.

Inventor： Gilles BESIN ,  Luis BRITO ,  Stephen G. HOGE ,  Edward HENNESSY ,  Mark CORNEBISE ,  Kerry BENENATO ,  Staci SABNIS ,  Michael W. DANNEMAN

IPC: A61K9/51 ,  C07K14/525 ,  A61P35/00 ,  C07K14/705 ,  A61K39/245

Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.

公开(公告)号：US20240226026A1

公开(公告)日：2024-07-11

申请号：US18551704

申请日：2022-03-23

Applicant: ModernaTX, Inc.

Inventor： Kerry E. BENENATO ,  Mark CORNEBISE ,  Edward HENNESSY ,  Mohindra SEEPERSAUD ,  Michael W. DANNEMAN

IPC: A61K9/51 ,  C07C233/36 ,  C07C233/62 ,  C07C233/78 ,  C07C311/32 ,  C07D205/04 ,  C07D207/16 ,  C07D213/74 ,  C07D231/12 ,  C07D271/07 ,  C07D285/10 ,  C07D307/24 ,  C07D309/08

CPC classification number: A61K9/5123 ,  C07C233/36 ,  C07C233/62 ,  C07C233/78 ,  C07C311/32 ,  C07D205/04 ,  C07D207/16 ,  C07D213/74 ,  C07D231/12 ,  C07D271/07 ,  C07D285/10 ,  C07D307/24 ,  C07D309/08

Abstract: The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.

公开(公告)号：US20230027864A1

公开(公告)日：2023-01-26

申请号：US17747618

申请日：2022-05-18

Applicant: ModernaTX, Inc.

Inventor： Gilles BESIN ,  Luis BRITO ,  Stephen G. HOGE ,  Edward HENNESSY ,  Mark CORNEBISE ,  Kerry BENENATO ,  Staci SABNIS ,  Michael W. DANNEMAN

IPC: A61K9/51 ,  A61P35/00 ,  A61K39/245 ,  C07K14/525 ,  C07K14/705

Abstract: The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.